{
    "title": "Novartis predicts rising sales and minimal disruption from coronavirus",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-7941551/Novartis-predicts-2020-growth-Cosentyx-Zolgensma-add-sales.html",
    "date": "2020-01-29",
    "keywords": [
        "company",
        "narasimhan",
        "coronavirus",
        "novartis",
        "business",
        "john",
        "basel",
        "year",
        "outbreak",
        "china",
        "outlook",
        "growth",
        "cosentyx",
        "core",
        "income",
        "revenue",
        "entresto",
        "miller",
        "jan",
        "vas",
        "profitability",
        "range",
        "disruption",
        "supply",
        "chain",
        "pfizer",
        "bar",
        "rival",
        "roche",
        "profit",
        "gmt",
        "dividend",
        "share",
        "threat",
        "fastestgrowing",
        "research",
        "development",
        "staff",
        "work",
        "home",
        "travel",
        "head",
        "unit",
        "richard",
        "saynor",
        "buffer",
        "drug",
        "portfolio",
        "cancer",
        "arthritis",
        "post",
        "fourthquarter",
        "group",
        "mix",
        "psoriasis",
        "medicine",
        "heart",
        "failure",
        "remedy",
        "gene",
        "therapy",
        "zolgensma",
        "acquisition",
        "size",
        "approach",
        "news",
        "conference",
        "humanity",
        "disease",
        "oncology",
        "way",
        "focus",
        "analyst",
        "nawrath",
        "rating",
        "stock",
        "cosentyxs",
        "period",
        "market",
        "reporting",
        "revill",
        "mark",
        "potter",
        "david",
        "goodman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}